Skip to main content
Shanxi Zhendong Pharmaceutical Co.,Ltd logo

Shanxi Zhendong Pharmaceutical Co.,Ltd — Investor Relations & Filings

Ticker · 300158 ISIN · CNE100000YR9 LEI · 300300P06SKYE9K9GJ93 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,108 across all filing types
Latest filing 2026-05-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300158

About Shanxi Zhendong Pharmaceutical Co.,Ltd

https://www.zdjt.com

Shanxi Zhendong Pharmaceutical Co., Ltd. focuses on the research, development, production, and marketing of a diverse range of healthcare products. Its core portfolio includes traditional Chinese medicine (TCM), chemical pharmaceuticals, and nutritional supplements. The company is particularly recognized for its oncology treatments, cardiovascular medications, and anti-infective drugs. A flagship product line is the Langdi series, which leads in the calcium supplement market. The organization operates an integrated industrial chain that spans from the standardized cultivation of medicinal herbs to the manufacturing of finished pharmaceutical products. By leveraging modern extraction technologies and clinical research, the company aims to modernize TCM applications. Its business activities extend across clinical therapeutics and consumer health, prioritizing quality control and innovation in drug formulation and delivery.

Recent filings

Filing Released Lang Actions
关于股东股份质押的公告
Regulatory Filings Classification · 61% confidence The document is a corporate announcement disclosing that the controlling shareholder has pledged its existing shares as collateral. This is not a change in board or management, not a financial report, not a dividend, and does not involve share issuance or buybacks by the company. It is also not an insider trade or voting result. Therefore, it falls under general regulatory announcements (RNS) as it does not match any more specific category.
2026-05-27 Chinese
关于参加山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会活动的公告
Regulatory Filings Classification · 60% confidence The document is an announcement by Shanxi Zhendong Pharmaceutical regarding its participation in an online investor reception day and annual performance briefing. It does not contain any actual financial statements or detailed presentation materials, nor is it the publication of an annual report itself. It serves as a regulatory announcement of an upcoming investor event, which falls under the general 'Regulatory Filings' category (RNS) as it does not match any more specific category.
2026-05-18 Chinese
北京大成律师事务所关于山西振东制药股份有限公司2025年年度股东会之法律意见书
Regulatory Filings Classification · 18% confidence The document is a legal opinion letter issued by a law firm regarding the convening procedures, attendee qualifications, meeting protocols, and vote results of the 2025 Annual General Meeting. It is not the AGM presentation itself, nor a standalone vote-results announcement by the company, nor a proxy solicitation or financial report. As there is no dedicated category for legal opinion letters, it falls into the general “Regulatory Filings” (RNS) fallback category.
2026-05-14 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an official announcement of the 2025 annual general shareholders’ meeting resolutions, detailing each proposal and the exact vote counts (agree, oppose, abstain) by shareholders, including breakdowns for small shareholders. It does not include financial statements or management discussion; rather, it is the formal declaration of voting results from the AGM. This matches the ‘Declaration of Voting Results & Voting Rights Announcements’ category.
2026-05-14 Chinese
关于第五期员工持股计划完成股票购买的公告
Transaction in Own Shares Classification · 89% confidence The document is an official announcement from the listed company regarding the completion of its fifth employee share ownership plan’s market purchase of its own shares (9,238,000 shares acquired via secondary market). This is not a dividend, earnings release, or management change; it is a transaction involving the company’s own shares under an employee stock ownership plan. Under our taxonomy, announcements of the company (or its employee plan) buying back or otherwise transacting in its own shares are classified as Transaction in Own Shares (POS).
2026-05-12 Chinese
关于股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the pledge of shares by a controlling shareholder. It details the number of shares pledged, the proportion of total shares, pledge terms, and assurances about the impact on the company. There are no financial statements, earnings data, or management discussion. The document is a formal disclosure about a shareholder's share pledge, which fits the category of a capital or financing update related to share pledges. The document length is short (1645 characters), and it is not an announcement of a report publication but a substantive disclosure. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2026-05-07 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.